Rosalind Advisors, Inc. 13D and 13G filings for Trevi Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-13 1:41 pm Purchase |
2025-02-13 | 13G | Trevi Therapeutics, Inc. TRVI |
Rosalind Advisors, Inc. | 1,062,500 1.200% |
312,500 (+41.67%) |
Filing |
| 2024-10-23 2:44 pm Sale |
2024-09-30 | 13G | Trevi Therapeutics, Inc. TRVI |
Rosalind Advisors, Inc. | 750,000 1.030% |
-641,577 (-46.10%) |
Filing |
| 2024-07-11 5:52 pm Purchase |
2024-06-28 | 13G | Trevi Therapeutics, Inc. TRVI |
Rosalind Advisors, Inc. | 1,391,577 1.980% |
465,561 (+50.28%) |
Filing |
| 2024-04-25 7:39 pm Sale |
2024-03-31 | 13G | Trevi Therapeutics, Inc. TRVI |
Rosalind Advisors, Inc. | 926,016 1.340% |
-1,573,977 (-62.96%) |
Filing |
| 2023-02-15 1:16 pm Purchase |
2022-12-31 | 13G | Trevi Therapeutics, Inc. TRVI |
Rosalind Advisors, Inc. | 2,499,993 4.200% |
314,329 (+14.38%) |
Filing |
| 2022-03-09 5:09 pm Purchase |
2022-02-28 | 13G | Trevi Therapeutics, Inc. TRVI |
Rosalind Advisors, Inc. | 2,185,664 8.500% |
2,185,664 (New Position) |
Filing |